Implantable lens maker Staar Surgical Co. said Thursday that it expects to report a 16 percent increase in revenue for the third quarter because of strong sales of a lens used to treat nearsightedness.
The Monrovia, Calif., company reports third-quarter results on Oct. 24. Staar said it expects to report $15.3 million in sales for the period, driven by a 31 percent increase in sales of Visian ICL, a permanently implanted lens used to treat myopia, or nearsightedness, and other vision problems.
The company also makes implantable lenses used following cataract surgery.
Shares of STAAR Surgical rose 14 cents, or 1.5 percent, to $9.39 Thursday afternoon.